Rhythm Pharmaceuticals, Inc. (BMV:RYTM)

Mexico · Delayed Price · Currency is MXN

1,866.76

-158.24 (-7.81%)

At close: Nov 18, 2025

94.86% (1Y)

Market Cap	108.95B
Revenue (ttm)	3.42B
Net Income (ttm)	-3.64B
Shares Out	n/a
EPS (ttm)	-55.94
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	599
Average Volume	3,380
Open	1,866.76
Previous Close	2,025.00
Day's Range	1,866.76 - 1,866.76
52-Week Range	1,800.00 - 2,025.00
Beta	n/a
RSI	78.94
Earnings Date	Feb 26, 2026

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 de... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2008

Employees 283

Stock Exchange Mexican Stock Exchange

Ticker Symbol RYTM

Full Company Profile

Financial Performance

In 2025, Rhythm Pharmaceuticals's revenue was $189.76 million, an increase of 45.83% compared to the previous year's $130.13 million. Losses were -$201.92 million, -23.68% less than in 2024.

Financial numbers in USD Financial Statements

News

Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity

-- -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks, including 12 Japanese patients and 10 supplemental patients with acquired hypothalamic obesity -- -...

6 hours ago - GlobeNewsWire

Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2025 Earnings Call Transcript

3 days ago - Seeking Alpha

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

-- Fourth quarter 2025 net product revenue from global sales of IMCIVREE ® (setmelanotide) of $57.3 million -- -- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic ob...

3 days ago - GlobeNewsWire

Rhythm Pharmaceuticals Is Well-Positioned, Analyst Says Could Capture Big Share Of Rare Obesity Market

RBC Capital Markets initiated coverage on Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM), citing it as a commercial-stage biotech pioneering the rare genetic obesity market.

10 days ago - Benzinga

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026

BOSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar...

12 days ago - GlobeNewsWire

Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit

BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar...

24 days ago - GlobeNewsWire

Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones

-- Q4 2025 preliminary net product revenues from global sales of IMCIVREE® (setmelanotide) of approximately $57 million for the fourth quarter of 2025, an 11% increase over Q3 2025 -- -- FY 2025 preli...

7 weeks ago - GlobeNewsWire

Rhythm: PWS Signal, HO Speed Bump, And The Case For A Rare-Obesity Blockbuster

Rhythm Pharmaceuticals, Inc. remains a compelling rare-disease obesity platform, with a maintained Buy rating driven by progress in HO, PWS, and oral MC4R agonists. PWS Phase 2 data for IMCIVREE show ...

2 months ago - Seeking Alpha

Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Preliminary Phase II Data of Setmelanotide in Prader-Willi Syndrome and Next Steps Transcript

2 months ago - Seeking Alpha

Rhythm Pharma Strikes Chord As Early PWS Trial Results Show Promise

Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) stock is higher on Thursday, after the company shared preliminary results from its exploratory Phase 2 trial of setmelanotide in patients with Prader-Willi s...

2 months ago - Benzinga

Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome

-- BMI and hyperphagia reductions have been observed in patients with PWS treated with setmelanotide at Month 3 (n=8) and Month 6 (n=5); 17 of 18 enrolled patients remain on therapy -- -- Promising re...

2 months ago - GlobeNewsWire

Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome

BOSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar...

2 months ago - GlobeNewsWire

Rhythm: Maintaining Strong Buy On Acquired Hypothalamic Obesity Drug Progress

Rhythm Pharmaceuticals, Inc. maintaining a Strong Buy rating, driven by IMCIVREE's growth and multiple late-stage expansion opportunities in rare genetic obesity indications. RYTM's IMCIVREE awaits FD...

3 months ago - Seeking Alpha

Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025

– Phase 3 TRANSCEND trial data showed setmelanotide achieved significant BMI reductions in patients with acquired hypothalamic obesity on concomitant treatment with GLP-1 therapy – – Analysis of data ...

3 months ago - GlobeNewsWire

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

-- FDA sets updated PDUFA goal date of March 20, 2026 – -- Company to hold conference today at 8:00 a.m. -- BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a gl...

4 months ago - GlobeNewsWire

Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program

BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar...